RT Book, Section
A1 Ciccone, Charles D.
A1 Bednarek, Melissa L.
A1 Miller, Kenneth L.
SR Print(0)
ID 1188531110
T1 Treatment of Infections III: Antifungal and Antiparasitic Drugs
T2 Pharmacology in Rehabilitation, 5e
YR 2022
FD 2022
PB F. A. Davis Company
PP New York, NY
SN 9781719645348
LK fadavisat.mhmedical.com/content.aspx?aid=1188531110
RD 2024/04/19
AB Humans  are  susceptible  to  infection  by  a  number  of  parasitic  species  of  fungi,  protozoa,  and  helminths  (worms).  Although  some  types  of  parasitic  infections  are  limited  or  unknown  in  developed  nations  such  as  the  United  States,  parasitic  infections  generally  represent  the  most  common  form  of  disease  worldwide.  These  infections  are  especially  prevalent  in  tropical  and  subtropical  environments  and  in  impoverished  areas  of  the  world  where  sanitation  and  hygiene  are  inadequate.  In  addition,  the  incidence  of  serious  fungal  and  other  parasitic  infections  has  been  increasing  in  industrialized  nations  because  of  the  increased  susceptibility  of  immunocompromised  patients  to  these  infections,  such  as  patients  with  HIV  or  those  receiving  immunosuppressant  drugs  after  organ  transplantation.1-3  Hence,  the  effective  pharmacological  treatment  of  these  infections  remains  an  important  topic  in  the  global  management  of  disease.